Intech Biopharm (ROCO:6461) FCF Margin %: -1,538.83% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6461 Intech Biopharm Ltd ROCO:6461
55 GF Score
Price NT$15.45
GF Value NT$87.86
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Intech Biopharm FCF Margin %?

Intech Biopharm ROCO:6461 -0.64% 55 FCF Margin % is -1,538.83% as of Dec. 2025. GuruFocus rates ROCO:6461 with a GF Score™ of 55/100 and a GF Value™ of NT$87.86 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 950 Biotechnology companies, Intech Biopharm ranks worse than 68.63% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Intech Biopharm's Free Cash Flow for the three months ended in Dec. 2025 was NT$-74.2 Mil. Intech Biopharm's Revenue for the three months ended in Dec. 2025 was NT$4.8 Mil. Therefore, Intech Biopharm's FCF Margin % for the quarter that ended in Dec. 2025 was -1,538.83%.

As of today, Intech Biopharm's current FCF Yield % is -15.43%.

The historical rank and industry rank for Intech Biopharm's FCF Margin % or its related term are showing as below:

ROCO:6461' s FCF Margin % Range Over the Past 10 Years
Min: -4142.99   Med: -963.93   Max: -395.38
Current: -395.38

During the past 13 years, the highest FCF Margin % of Intech Biopharm was -395.38%. The lowest was -4142.99%. And the median was -963.93%.

ROCO:6461's FCF Margin % is ranked worse than
68.63% of 950 companies
in the Biotechnology industry
Industry Median: -81.28 vs ROCO:6461: -395.38

Intech Biopharm FCF Margin % Related Terms

Intech Biopharm FCF Margin % Historical Data

* Premium members only.

The historical data trend for Intech Biopharm's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intech Biopharm FCF Margin % Chart

Intech Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -570.48 -851.65 -906.64 -786.44 -395.38

Intech Biopharm Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -605.65 -1,619.10 -102.31 -1,883.97 -1,538.83

ROCO:6461 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Intech Biopharm's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intech Biopharm FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intech Biopharm's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Intech Biopharm's FCF Margin % falls into.


ROCO:6461
55GF Score
Intech Biopharm Ltd ROCO:6461
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intech Biopharm FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Intech Biopharm's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-425.142/107.527
=-395.38 %

Intech Biopharm's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-74.233/4.824
=-1,538.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -1,538.83% mean?
Intech Biopharm (ROCO:6461) has a FCF Margin % of -1,538.83% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Intech Biopharm and its competitors. According to the industry distribution chart, Intech Biopharm ranks #652 out of 950 companies in the Biotechnology industry, placing it in the top 68.6%.
Is Intech Biopharm's FCF Margin % too high?
Intech Biopharm's current FCF Margin % is -1,538.83%. Based on the distribution chart, Intech Biopharm ranks #652 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Intech Biopharm has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intech Biopharm's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Intech Biopharm ranks #652 out of 950 companies for FCF Margin %. This places Intech Biopharm in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Intech Biopharm and its competitors. Intech Biopharm's current FCF Margin % is -1,538.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intech Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Intech Biopharm (ROCO:6461) is currently considered Possible Value Trap. The stock's GF Value™ is NT$87.86, compared to a current price of NT$15.45 — trading 82.4% below its estimated fair value. The current FCF Margin % is -1,538.83%. Intech Biopharm's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Intech Biopharm (ROCO:6461), the current FCF Margin % is -1,538.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intech Biopharm (ROCO:6461) Overvalued in 2026?

Based on GuruFocus' analysis, Intech Biopharm stock appears to be undervalued. The current stock price of NT$15.45 is trading 82.4% below its estimated GF Value™ of NT$87.86. GuruFocus considers Intech Biopharm to be Possible Value Trap.

Key valuation signals for ROCO:6461:

  • FCF Margin %: -1,538.83%
  • GF Value™: NT$87.86 vs. price of NT$15.45 (82.4% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6461 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intech Biopharm Business Description

Address No.36, Ruiguang Road, 3rd Floor, Lane 358, Neihu District, Taipei, TWN, 114
Intech Biopharm Ltd is engaged in pharmaceutical R&D and sales. The company focuses on the development and manufacturing of new combinations, new formulations, and generic drugs with high barriers for the treatment of respiratory diseases. It owns the patented MDI platform iLEF (Inhaled Low Ethanol Formulation). The company operates in a single-industry segment, mainly engaged in R&D of technology and sale of pharmaceuticals.
55GF Score

Get the complete analysis for ROCO:6461

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.45
Price
NT$87.86
GF Value